ST Pharm Co.,Ltd. announced a private placement to issue Series 2 unregistered non-guaranteed privately placed convertible bonds for the gross proceeds of KRW 100,000,000,000 on August 7, 2023. The transaction will include participation from new investors, NH Investment & Securities Co., Ltd., KB Securities Co., Ltd., JB Woori Capital Co., Ltd, KIWOOM capital Co.,Ltd., EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., Hanyang Securities Co. Ltd., Kiwoom Securities Co., Ltd., Hi Investment & Securities Co.,Ltd., Lindeman Innovation Growth PEF, a fund managed by, Lindeman Asia Investment Corporation, Korea Investment & Securities Co., Ltd., Shinhan Capital Co., Ltd., LYFE Capital Fund IV (Dragon), L.P., LYFE Capital Fund IV (Dragon), L.P., Hanyang Time Mezzanine New Technology Fund, Cape-the-J-Paros Mezzanine New Technology Fund, Samsung Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on August 9, 2023.